Movano Health, a wearable maker, has recently announced a partnership with the Massachusetts Institute of Technology (MIT) to utilize the continuous health monitoring capabilities of its Evie Ring in a study focused on COVID and chronic Lyme disease. The ring will be used in MIT’s MAESTRO study, which aims to identify biomarkers that can predict the development of chronic conditions from acute infections.
The study will involve the analysis of 300 adults aged 18 to 35 with acute or chronic Lyme disease, individuals experiencing long COVID, and participants in a control group. Movano’s Evie Ring gathers data on the wearer’s heart rate, SpO₂ levels, sleep quality, activity levels, and menstrual cycle symptoms.
Dr. Michal Caspi Tal, associate scientific director at the MIT Center for Gynepathology Research and head of the Tal Research Group, expressed enthusiasm about incorporating the Evie Ring into the clinical study. The goal is to better understand the progression of long COVID and chronic Lyme disease and gain insight into why some individuals recover swiftly from mild infections while others endure prolonged suffering.
Movano Health has seen positive financial results since the launch of its Evie Ring. The company’s stock is currently trading at around $0.40 per share, and it reported significant progress with the commercialization of its wearable device. Movano Health secured a $24 million private placement, including investments from a medical device company and members of its board of directors and management team, to support its growth and development efforts.
